BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Manual for Tracking down the Nearby Business sectors and Marketplaces - 2Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- 3California is completely free of drought for the first time in 25 years
- 4Instructions to Plan for Your Teeth Substitution Methodology
- 5Early diagnosis leads King Charles to scale back cancer treatment in the new year
- The Response Uncovered: Disentangling the Secrets of the Universe
- 10 Energizing Vocations in the Innovation Business
- Manual for 10 Scrumptious Specialty Mixed drinks
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- Language Learning Applications for Voyagers
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- The Best 10 Innovation Advancements of the Year
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
